<DOC>
	<DOC>NCT01833533</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and antiviral activity of ABT-450/ritonavir/ABT- 267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) with and without ribavirin (RBV) in patients with chronic hepatitis C virus genotype 1a (HCV GT1a) infection without cirrhosis.</brief_summary>
	<brief_title>A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection</brief_title>
	<detailed_description>A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and antiviral activity of the combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 with and without ribavirin (RBV) in treatment-naive, noncirrhotic participants with chronic hepatitis C virus genotype 1a (HCV GT1a) infection.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Females must be practicing specific forms of birth control on study treatment, or be postmenopausal for more than 2 years or surgically sterile Chronic hepatitis C, genotype 1ainfection (HCV RNA level greater than or equal to 10,000 IU/mL at screening) Subject has never received antiviral treatment for hepatitis C infection No evidence of liver cirrhosis Significant liver disease with any cause other than HCV as the primary cause Positive hepatitis B surface antigen or antihuman immunodeficiency virus antibody Positive screen for drugs or alcohol Significant sensitivity to any drug Use of contraindicated medications within 2 weeks of dosing Abnormal laboratory tests</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Hepatitis C Genotype 1a</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Treatment-Na√Øve</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Paritaprevir</keyword>
	<keyword>Ombitasvir</keyword>
	<keyword>Dasabuvir</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Viekira PAK</keyword>
</DOC>